Autres langues 89bio, Inc.

Actions

ETNB

US2825591033

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 02/05/2024			Varia. 5j.	Varia. 1 janv.
8,86 ^USD	+1,26%		+7,39%	-20,68%

17/04	89bio, Inc. nomme Martin Babler à son conseil d'administration	CI
03/04	Un initié de 89bio a vendu des actions d'une valeur de 575 153 $, selon un récent dépôt auprès de la SEC	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH	22:05
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors	17/04
89bio, Inc. Appoints Martin Babler to Its Board of Directors	17/04
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/04
89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing	03/04
Sector Update: Health Care Stocks Gain Wednesday Afternoon	27/03
89bio's Liver Disease Drug Candidate Pegozafermin Gets EMA Priority Medicines Status	27/03
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis	27/03
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis	27/03
89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis and Compensated Cirrhosis	27/03
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis	12/03
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis	12/03
89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis, Formerly Known as Nonalcoholic Steatohepatitis	12/03
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(4)	11/03
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	08/03
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	08/03
North American Morning Briefing : Stock Futures -2-	08/03
89bio to Participate in the Leerink Partners Global Biopharma Conference	05/03
Thinking about buying stock in Aadi Bioscience, Bitdeer Technologies, Aquestive Therapeutics, 89bio, or Energem?	04/03
Top Premarket Gainers	04/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues 89bio, Inc.

Actions

ETNB

US2825591033

Autres langues

Filtres